These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

484 related articles for article (PubMed ID: 16807281)

  • 1. Differential effects of oral conjugated equine estrogen and transdermal estrogen on atherosclerotic vascular disease risk markers and endothelial function in healthy postmenopausal women.
    Ho JY; Chen MJ; Sheu WH; Yi YC; Tsai AC; Guu HF; Ho ES
    Hum Reprod; 2006 Oct; 21(10):2715-20. PubMed ID: 16807281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of transdermal hormone replacement therapy on the monocyte chemoattractant protein-1 concentrations and other vascular inflammatory markers and on endothelial function in postmenopausal women.
    Sumino H; Ichikawa S; Ohyama Y; Takahashi T; Saito Y; Nakamura T; Kanda T; Kurabayashi M
    Am J Cardiol; 2005 Jul; 96(1):148-53. PubMed ID: 15979455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
    Stanosz S; Zochowska E; Safranow K; Sieja K; Stanosz M
    Metabolism; 2009 Jan; 58(1):1-7. PubMed ID: 19059524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different effect of hormone replacement therapy, DHEAS and tibolone on endothelial function in postmenopausal women with increased cardiovascular risk.
    Silvestri A; Gambacciani M; Vitale C; Monteleone P; Ciaponi M; Fini M; Genazzani AR; Mercuro G; Rosano GM
    Maturitas; 2005 Apr; 50(4):305-11. PubMed ID: 15780531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of lower dosage of oral conjugated equine estrogen on inflammatory markers and endothelial function in healthy postmenopausal women.
    Wakatsuki A; Ikenoue N; Shinohara K; Watanabe K; Fukaya T
    Arterioscler Thromb Vasc Biol; 2004 Mar; 24(3):571-6. PubMed ID: 14699021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of continuation of postmenopausal hormone replacement therapy: transdermal versus oral estrogen.
    Ettinger B; Pressman A; Bradley C
    Menopause; 1998; 5(3):152-6. PubMed ID: 9774760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different effects of transdermal and oral hormone replacement therapy on the renin-angiotensin system, plasma bradykinin level, and blood pressure of normotensive postmenopausal women.
    Ichikawa J; Sumino H; Ichikawa S; Ozaki M
    Am J Hypertens; 2006 Jul; 19(7):744-9. PubMed ID: 16814131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different effects of oral conjugated estrogen and transdermal estradiol on arterial stiffness and vascular inflammatory markers in postmenopausal women.
    Sumino H; Ichikawa S; Kasama S; Takahashi T; Kumakura H; Takayama Y; Kanda T; Kurabayashi M
    Atherosclerosis; 2006 Dec; 189(2):436-42. PubMed ID: 16469323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sex hormone replacement therapy and modulation of vascular function in cardiovascular disease.
    Koledova VV; Khalil RA
    Expert Rev Cardiovasc Ther; 2007 Jul; 5(4):777-89. PubMed ID: 17605655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of transdermal estrogens on endothelial function in postmenopausal women with coronary disease.
    Blümel JE; Castelo-Branco C; Leal T; Gallardo L; Saini J; Ferron S; Haya J
    Climacteric; 2003 Mar; 6(1):38-44. PubMed ID: 12725663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vasoactive biomarkers and oxidative stress in healthy recently postmenopausal women treated with hormone replacement therapy.
    Maffei S; Mercuri A; Prontera C; Zucchelli GC; Vassalle C
    Climacteric; 2006 Dec; 9(6):452-8. PubMed ID: 17085378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Investigation of atherosclerosis in postmenopausal women: alteration of atherosclerosis-associated factors and vascular atherosclerosis by oral and transdermal estrogen replacement].
    Sumino H; Murakami M
    Rinsho Byori; 2013 Mar; 61(3):256-62. PubMed ID: 23785796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of transdermal and oral estrogen replacement on lipids and glucose metabolism in postmenopausal women with type 2 diabetes mellitus.
    Araújo DA; Farias ML; Andrade AT
    Climacteric; 2002 Sep; 5(3):286-92. PubMed ID: 12419087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality of life assessment in a chemoprevention trial: fenretinide and oral or transdermal HRT.
    Serrano D; Mariani L; Mora S; Guerrieri-Gonzaga A; Cazzaniga M; Daldoss C; Ramazzotto F; Feroce I; Decensi A; Bonanni B
    Maturitas; 2006 Aug; 55(1):69-75. PubMed ID: 16500052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exercise as an alternative to oral estrogen for amelioration of endothelial dysfunction in postmenopausal women.
    Harvey PJ; Picton PE; Su WS; Morris BL; Notarius CF; Floras JS
    Am Heart J; 2005 Feb; 149(2):291-7. PubMed ID: 15846267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of postmenopausal hormone replacement therapy on body fat composition.
    Yüksel H; Odabasi AR; Demircan S; Köseoğlu K; Kizilkaya K; Onur E
    Gynecol Endocrinol; 2007 Feb; 23(2):99-104. PubMed ID: 17454160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum estrogen level after hormone replacement therapy and body mass index in postmenopausal and bilaterally ovariectomized women.
    Yasui T; Uemura H; Umino Y; Takikawa M; Saito S; Kuwahara A; Matsuzaki T; Maegawa M; Furumoto H; Miura M; Irahara M
    Maturitas; 2005 Jan; 50(1):19-29. PubMed ID: 15590210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High C-reactive protein levels are associated with oral hormonal menopausal therapy but not with intrauterine levonorgestrel and transdermal estradiol.
    Blumenfeld Z; Boulman N; Leiba R; Siegler E; Shachar S; Linn R; Levy Y
    Scand J Clin Lab Invest; 2007; 67(3):257-63. PubMed ID: 17454839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased levels of C-reactive protein after oral hormone replacement therapy may not be related to an increased inflammatory response.
    Silvestri A; Gebara O; Vitale C; Wajngarten M; Leonardo F; Ramires JA; Fini M; Mercuro G; Rosano GM
    Circulation; 2003 Jul; 107(25):3165-9. PubMed ID: 12796135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of oral and transdermal hormone replacement therapy on C-reactive protein levels and other inflammatory markers in women with high risk of thrombosis.
    Eilertsen AL; Høibraaten E; Os I; Andersen TO; Sandvik L; Sandset PM
    Maturitas; 2005 Oct; 52(2):111-8. PubMed ID: 16186073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.